Crime & Justice · 19 views
AACR: Zedoresertib and lunresertib combination shows promising antitumor activity
For patients with advanced solid tumors harboring specific genetic alterations, the first-in-class synthetic lethal combination of WEE1 inhibitor zedoresertib plus PKMYT1 inhibitor lunresertib demonstrated promising antitumor activity and…
AI Summary
Researchers at The University of Texas MD Anderson Cancer Center have reported promising results from a Phase I clinical trial. The trial involved a combination of two inhibitors: zedoresertib, which targets WEE1, and lunresertib, which targets PKMYT1.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Crime & Justice
Continue reading recent Crime & Justice coverage
- Hawaii high court grapples with $222M taken from Maui wildfire settlementContinue reading
- Ninth Circuit questions executive authority over Arctic refuge oil and gas leasesContinue reading
- California museum sued over Renaissance painting looted by NazisContinue reading
- Spat between justices deepens Brazil Supreme Court crisisContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow